|
1
|
Yendamuri S, Caty L, Pine M, Adem S,
Bogner P, Miller A, Demmy TL, Groman A and Reid M: Outcomes of
sarcomatoid carcinoma of the lung: A surveillance, epidemiology,
and end results database analysis. Surgery. 152:397–402. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 world health organization
classification of lung tumors: impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pelosi G, Sonzogni A, De Pas T, Galetta D,
Veronesi G, Spaggiari L, Manzotti M, Fumagalli C, Bresaola E, Nappi
O, et al: Review article: Pulmonary sarcomatoid carcinomas: A
practical overview. Int J Surg Pathol. 18:103–120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vieira T, Girard N, Ung M, Monnet I, Cazes
A, Bonnette P, Duruisseaux M, Mazieres J, Antoine M, Cadranel J and
Wislez M: Efficacy of first-line chemotherapy in patients with
advanced lung sarcomatoid carcinoma. J Thorac Oncol. 8:1574–1577.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen M, Yang Q, Xu Z, Luo B, Li F, Yu Y
and Sun J: Survival analysis and prediction model for pulmonary
sarcomatoid carcinoma based on SEER database. Front Oncol.
11:6308852021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsao AS, Scagliotti GV, Bunn PA Jr,
Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU,
McWilliams A, Tsao MS, et al: Scientific advances in lung cancer
2015. J Thorac Oncol. 11:613–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Terra SB, Jang JS, Bi L, Kipp BR, Jen J,
Yi ES and Boland JM: Molecular characterization of pulmonary
sarcomatoid carcinoma: analysis of 33 cases. Mod Pathol.
29:824–831. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martin LW, Correa AM, Ordonez NG, Roth JA,
Swisher SG, Vaporciyan AA, Walsh GL and Rice DC: Sarcomatoid
carcinoma of the lung: A predictor of poor prognosis. Ann Thorac
Surg. 84:973–980. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ouziane I, Boutayeb S, Mrabti H, Lalya I,
Rimani M and Errihani H: Sarcomatoid carcinoma of the lung: A model
of resistance of chemotherapy. N Am J Med Sci. 6:342–345. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fallet V, Saffroy R, Girard N, Mazieres J,
Lantuejoul S, Vieira T, Rouquette I, Thivolet-Bejui F, Ung M,
Poulot V, et al: High-throughput somatic mutation profiling in
pulmonary sarcomatoid carcinomas using the lungcarta panel:
Exploring therapeutic targets. Ann Oncol. 26:1748–1753. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schrock AB, Li SD, Frampton GM, Suh J,
Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, et al:
Pulmonary sarcomatoid carcinomas commonly harbor either potentially
targetable genomic alterations or high tumor mutational burden as
observed by comprehensive genomic profiling. J Thorac Oncol.
12:932–942. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaira K, Horie Y, Ayabe E, Murakami H,
Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Kondo H, et al:
Pulmonary pleomorphic carcinoma: A clinicopathological study
including EGFR mutation analysis. J Thorac Oncol. 5:460–465. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakagomi T, Goto T, Hirotsu Y, Shikata D,
Yokoyama Y, Higuchi R, Amemiya K, Okimoto K, Oyama T, Mochizuki H
and Omata M: New therapeutic targets for pulmonary sarcomatoid
carcinomas based on their genomic and phylogenetic profiles.
Oncotarget. 9:10635–10649. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lococo F, Gandolfi G, Rossi G, Pinto C,
Rapicetta C, Cavazza A, Cesario A, Galeone C, Paci M and Ciarrocchi
A: Deep sequencing analysis reveals that KRAS mutation is a marker
of poor prognosis in patients with pulmonary sarcomatoid carcinoma.
J Thorac Oncol. 11:1282–1292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Wang D, Zhao Q, Ren D, Ren F, Chen
G, Liu H and Chen J: Clinical significance and next-generation
sequencing of chinese pulmonary sarcomatoid carcinoma. Sci Rep.
7:39472017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tong JH, Yeung SF, Chan AW, Chung LY, Chau
SL, Lung RWM, Tong CY, Chow C, Tin EKY, Yu YH, et al: MET
Amplification and exon 14 splice site mutation define unique
molecular subgroups of non-small cell lung carcinoma with poor
prognosis. Clin Cancer Res. 22:3048–3056. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Jia Y, Stoopler MB, Shen Y, Cheng
H, Chen J, Mansukhani M, Koul S, Halmos B and Borczuk AC:
Next-generation sequencing of pulmonary sarcomatoid carcinoma
reveals high frequency of actionable MET gene mutations. J Clin
Oncol. 34:794–802. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen X, Zhang Y, Lu J, Xu C, Liang J, Wang
F, Sun W, Fang S, Yuan J, Wang H, et al: Pulmonary sarcomatoid
carcinoma with ALK rearrangement: Frequency, clinical-pathologic
characteristics, and response to ALK inhibitor. Transl Oncol.
10:115–120. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Naito M, Tamiya A, Takeda M, Taniguchi Y,
Saijo N, Naoki Y, Okishio K, Yoon H, Kasai T, Matsumura A and Atagi
S: A High PD-L1 expression in pulmonary pleomorphic carcinoma
correlates with parietal-pleural invasion and might predict a poor
prognosis. Intern Med. 58:921–927. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang Z, Xu J, Li R, Gao Y and He J: PD-L1
and CD47 co-expression in pulmonary sarcomatoid carcinoma: A
predictor of poor prognosis and potential targets of future
combined immunotherapy. J Cancer Res Clin Oncol. 145:3055–3065.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu L, Tao NN, Liang B, Li DW, Li HC and Su
LL: Use of PD-1 inhibitor tislelizumab in the treatment of advanced
pulmonary sarcomatoid carcinoma: A case report. Thorac Cancer.
13:502–505. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matsumoto Y, Miura T, Horiuchi H and Usui
K: The successful treatment of pulmonary pleomorphic carcinoma with
pembrolizumab: A case report. Case Rep Oncol. 10:752–757. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Domblides C, Leroy K, Monnet I, Mazières
J, Barlesi F, Gounant V, Baldacci S, Mennecier B, Toffart AC,
Audigier-Valette C, et al: Efficacy of immune checkpoint inhibitors
in lung sarcomatoid carcinoma. J Thorac Oncol. 15:860–866. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong
W, Zhang Y, Zhou X, Wang Z, Wang Y, et al: The binding of an
anti-PD-1 antibody to FcgammaRIota has a profound impact on its
biological functions. Cancer Immunol Immunother. 67:1079–1090.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai
Y, Liu T, Zhou Q, Zhao J, Shu Y, et al: Tislelizumab in chinese
patients with advanced solid tumors: An open-label,
non-comparative, phase 1/2 study. J Immunother Cancer.
8:e0004372020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee A and Keam SJ: Tislelizumab: First
approval. Drugs. 80:617–624. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang H and Wang M: Prospect of
immunotherapy combined with anti-angiogenic agents in patients with
advanced non-small cell lung cancer. Cancer Manag Res.
11:7707–7719. 2019. View Article : Google Scholar : PubMed/NCBI
|
